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Background: Our knowledge of global protein-protein interaction (PPI) networks in complex organisms such as
humans is hindered by technical limitations of current methods.
Results: On the basis of short co-occurring polypeptide regions, we developed a tool called MP-PIPE capable of
predicting a global human PPI network within 3 months. With a recall of 23% at a precision of 82.1%, we predicted
172,132 putative PPIs. We demonstrate the usefulness of these predictions through a range of experiments.
Conclusions: The speed and accuracy associated with MP-PIPE can make this a potential tool to study individual
human PPI networks (from genomic sequences alone) for personalized medicine.
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Protein-protein interactions (PPIs) are essential molecular
interactions that define the biology of a cell, its develop-
ment and responses to various stimuli. Physical interac-
tions between proteins can form the basis for protein
functions, communications, and regulation and controls
within a cell. Such interactions can result in the formation
of protein complexes that perform specific tasks. Similarly,
internal and external signals are often realized and com-
municated through the formation of stable or transient
PPIs. Due to their central importance to the integrity of
communication networks within a cell, PPIs are thought
to involve important targets for drug discovery [1] and are
linked to a number of cellular conditions and diseases [2].
Our current knowledge of global PPI networks in dif-
ferent organisms is hindered by the constraints and limi-
tations of existing experimental techniques amenable to
high throughput PPI studies, such as yeast-two-hybrid
(Y2H) and affinity purification combined with mass
spectrometry (APMS). While both of these techniques* Correspondence: ashkan_golshani@carleton.ca
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article, unless otherwise stated.have been successfully applied to global PPI detection in
the yeast, Saccharomyces cerevisiae [3-6], they suffer from
significant shortcomings highlighted by the lack of overlap
observed between the PPI data in different reports. The
two benchmark large-scale yeast APMS investigations
have less than 25% overlap and this overlap is even less for
the two classic Y2H projects [7]. Only 24 PPIs are shared
between all four studies, further highlighting the gap in
our understanding of global PPI networks. Although
recent technical improvements are expected to increase
the confidence of the detected PPIs and hence fill some
of the current gap of knowledge, increasing the coverage
and quality of PPI networks remains an important chal-
lenge [3,7-10].
Computational tools offer time and cost effective alter-
natives to traditional wet-lab PPI detection tools. They
may also be used as “filters” to increase confidence in
data derived from wet-lab experiments [7,11]. Like other
techniques, most computational tools also suffer from
notable deficiencies. For example, most computational
methods rely heavily on previously reported data. As-
suming that there are inherent discrepancies in the
training data, the accuracies of such tools to detect new
interactions are often questionable. Moreover, novelntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.biomedcentral.com/1471-2105/15/383interaction domains or motifs are likely to be missed by
methods that rely heavily on the structures or other
high-level features of protein pairs known to interact.
Another major shortcoming of computational tools is
that they are often too computationally intensive, mak-
ing them impossible to use for proteome-wide analysis.
To date, no comprehensive all-against-all analysis of the
entire human PPI network has been possible.
A small number of large-scale computational PPI pre-
diction methods have recently been published (e.g.
[12-14]). Although these methods have provided import-
ant contributions to the field, they are not applicable to
the entire human proteome due to computational com-
plexity, availability of input protein features, or unaccept-
ably high false positive rates. For example, a recent study
by Elefsinioti et al. examined five million protein pairs and
predicted 94,009 “high confidence” interactions [13]. Given
a conservative estimate of 22,000 human proteins, leading
to 242 million possible pairs, Elefsinioti et al. have exam-
ined only 2% of the potential interactome while others
have examined just over 7% [12] and 12.4% [14] of the
total interactome. Presumably these methods were limited
to examining only small subsets of protein pairs due to
computational complexity (i.e. runtime) or the availability
of input protein features. For example, the method of
Elefsinioti et al. [13] requires 18 complex features for each
protein relating to annotated function, sequence-derived
attributes, and network structure. Likewise, the method of
Zhang et al. [14] requires structural information for both
proteins in the putative interaction and is therefore only
applicable to 13,000 human proteins (even with homology-
based models). When considering protein pairs rather than
individual proteins, approximately 50% sequence coverage
results in an examination of at most 25% of the possible
PPIs. In fact, Zhang et al. report that they were able to
develop models for 36 million interactions, representing
12.4% of the 242 million possible interactions. Even if
these methods could be applied to all human protein
pairs, typical false positive rates will render existing
methods unusable on larger data sets. For example, con-
sidering that the method of Elefsinioti et al. [13] predicts
94,009 “high confidence” interactions among only 1.6%
of protein pairs, then we can reasonably expect nearly 6
million “high confidence” predicted interactions if their
method were to be applied to the entire human prote-
ome. This is an order of magnitude higher than the lar-
gest current estimate of the true size of the human
interactome [13], leaving the experimenter to weed
through a multitude of false positive predictions to find the
few true interactions. Likewise, using a previously pub-
lished computational method [15], Zhang et al. recently
reported [14] a false positive rate implying 41.2% preci-
sion, and their recall over an independent test set of
24,000 newly reported PPIs is less than 7%. Consequently,there is a need for the development of efficient tools that
are readily amenable to proteome-scale PPI prediction.
This is especially important as the field of personalized
medicine will benefit tremendously from a fast and accur-
ate method that can predict the global PPI maps of differ-
ent individuals from their genomic sequences alone.
A subset of cellular PPIs is mediated by defined short,
linear polypeptide sequences [16-18]. Leveraging this
fact, a number of computational tools have been devel-
oped to detect PPIs solely on the basis of primary
sequence [11,19,20]. Such approaches do not rely on
known structures or other protein features that are not
easily deduced from primary protein sequences, and are
thus, in principle, able to interrogate portions of the
proteome that are inaccessible to other methods. Some
of their predictions have been confirmed by tandem
affinity purification [19], in vitro binding assays [21], and
in vivo functional analysis [22]. An added benefit of
sequence-based PPI prediction is that short polypeptide
sequences in one organism can be used to predict PPIs
in another [23]. We note that, while the wide applicabil-
ity of sequence-based PPI prediction methods is clearly
a strength, in not using structural predictions, such tech-
niques may be unable to account for structural features
such as binding site accessibility or widespread contacts
between non-contiguous residues.
We have developed a computational tool termed the
Protein Interaction Prediction Engine (PIPE) that uses
co-occurrence of short polypeptide regions to detect
novel PPIs in S. cerevisiae [19]. Although PIPE was able
to analyze potential PPIs within certain proteomes, ap-
plying this tool to more complex proteomes remained
infeasible due to computational complexity. Analyzing
the ~242 million protein pairs in the human proteome
was estimated to require approximately 6.3 million CPU-
hours of computation. In order to study the human PPI
network, we developed a new Massively Parallel (MP)
version of PIPE, which we call MP-PIPE. MP-PIPE over-
comes some of the limitations of existing methods
through computational acceleration of the algorithm
(speed) and improved precision. We present a compre-
hensive all-against-all (pair-wise) analysis of the human
proteome and study its biological properties. We then
demonstrate the accuracy and utility of the MP-PIPE
inferred interactome using a range of functional assays.
Results and discussion
MP-PIPE performance and scalability enables
computational scan of entire human proteome
One of the main issues when predicting human protein
interactions on a large scale, which does not occur for
simpler organisms such as S. cervisiae or C. elegans, is the
complexity of the human proteome. More precisely, when
predicting human protein interactions using previous
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http://www.biomedcentral.com/1471-2105/15/383methods [22], the compute time to process a single hu-
man protein pair can vary between several seconds and
more than 12 hours. This effect has so far only been
observed for the human protein interactions. Our previous
method [22] was ranked highly in terms of prediction ac-
curacy in an independent comparison study [24]. How-
ever, it would be unable to process all human protein pairs
in our lifetime (approximately 6.3 million CPU-hours of
computation). Therefore, we developed an algorithm
called MP-PIPE, capable of performing global PPI analysis
of the human proteome. Although the task of performing
a proteome-wide, all-to-all prediction within the human
proteome is still extremely computationally expensive for
MP-PIPE, it still remained a feasible task and was com-
pleted within three months though massive parallelization.
From a Computer Science perspective, the main challenge
is the massive load imbalance of the parallelization. As
shown in Figure 1A, for the vast majority of protein pairs,
protein interaction prediction can be performed in sec-
onds. However, for some protein pairs, the process takes
minutes or hours, more than 12 hours in 8,000 extremeA
Figure 1 MP-PIPE benchmark performance. A) Distribution of running t
bars indicate approximate number of protein pairs with a running time wit
per worker on the large cluster. Average running times for 5,000 random p
(large number of threads), using one worker process. C) Performance for d
for 500,000 random protein pairs, using 512 threads per worker.cases. Solving this load imbalance in an efficient manner is
the main computational contribution of MP-PIPE.
In the following, we discuss the runtime performance
of MP-PIPE on different hardware architectures which
eventually enabled us to perform global PPI analysis of a
human cell within three months. More precisely, we
tested our MP-PIPE solution on three different compute
clusters. These clusters included a six node cluster with
24 total compute cores (small cluster), a 32 node cluster
with 128 total compute cores (medium cluster), and a 50
node cluster with 6,400 total hardware supported threads
(large cluster). The performance of MP-PIPE was initially
tested on a single large cluster node with varying numbers
of threads, and then in a second test we increased the
number of nodes (see details in Methods section). The test
data set consisted of 50,000 random protein pairs. How-
ever, this data set proved to be too large to compute using
a small number of threads, so a subset containing 5,000
random pairs was used to examine the runtime perform-
ance of the code with 1–16 threads and then the full
50,000 pair data set was used for tests with 16 or more1
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Table 1 Confusion matrix for the leave-one-out
cross-validation tests used to determine the prediction
accuracy of MP-PIPE
Known
interacting
pairs
Assumed
non-interacting
pairs
Total
Predicted to Interact 9,586 (TP) 50 (FP) 9,636
Predicted not to Interact 32,092 (FN) 99,950 (TN) 132,042
Total 41,678 100,000 141,678
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smaller 5,000 pair subset, runtimes were extrapolated to
estimate the runtime over the full 50,000 pair dataset. The
results are shown in Figure 1. The speedup curve shown
in Figure 1B shows a dramatic performance improvement
using up to 128 threads and then a slight improvement
from there up to 512 threads. We found that using more
than 512 threads creates memory problems. For the sec-
ond test, we increased the number of large cluster nodes
used, where each node ran one MP-PIPE worker with 512
worker threads. The results are shown in Figure 1C. The
performance of MP-PIPE scales almost linearly as the
number of compute nodes increases. This scalability prop-
erty of MP-PIPE enabled us to perform global PPI analysis
of the human proteome within three months.
Verification of MP-PIPE against experimental data
As with other PPI prediction methods, MP-PIPE relies
on previously reported interaction data to make its pre-
dictions. The quality of the predictions made is inher-
ently determined on the quality of this input data. To
determine the prediction accuracy of MP-PIPE for hu-
man PPIs we conducted a leave-one-out (LOO test) test
of MP-PIPE using the 41,678 experimentally verified,
high-confidence human PPIs taken from BioGrid and
100,000 randomly chosen negative protein pairs (as-
sumed to not interact). Choosing negative data in this
way avoids sources of bias introduced by other methods
(e.g. choosing pairs of proteins that do not appear in any
BioGrid records may bias the negative set towards mem-
brane proteins not readily amenable to experimental
verification techniques [25,26]). The LOO tests were
conducted as follows: MP-PIPE was run 41,678 times,
one for each experimentally verified interacting protein
pair (A, B). For each test run (A, B), we removed the
known interaction (A, B) from the database. In this
manner, we create a state where MP-PIPE is not aware
of the experimentally verified PPI (A, B), as if that inter-
action had not been measured yet. We then asked
MP-PIPE to predict whether or not proteins A and B
interact. The same was then done for the negative set of
randomly selected protein pairs that were expected to
not interact. Once finished, the 141,678 total MP-PIPE
predictions made were sorted by their PIPE score. Exam-
ining this sorted list allows us to set our decision thresh-
old operating point. Given any “accept threshold” (see
Methods for details on these thresholds), we can then
see how many false positives and negatives were pro-
duced during our 141,678 test runs. Given the expected
ratio of 100 non-interacting protein pairs for each inter-
acting protein pair, typically a threshold that achieves an
extremely high specificity (99.95%) is chosen in order to
minimize out false positive rate. At the chosen operating
point, MP-PIPE produced 9,586 true positives (TP),99,950 true negatives (TN), 50 false positives (FP) and
32,092 false negatives (FN) from the 141,678 total test
predictions made. These results are summarized in the
confusion matrix in Table 1.
Since the ratio of known interacting pairs to assumed
non-interacting pairs in our test set (i.e. 41,678:100,000)
is not representative of the true ratio expected among all
protein pairs within the H. sapiens proteome, the results
in the above confusion matrix require adjustment. This
adjustment to account for the true prevalence of PPIs
among all protein pairs leads to a more conservative and
realistic estimate of predictive performance of MP-PIPE.
We have used a ratio of 100 non-interacting protein
pairs per interacting pair. We feel this is a more realistic
estimate given the expected sparsity of the actual inter-
action network and the range of estimates reported in
previous studies [24,27]. The ratio-adjusted confusion
matrix adjusted for this ratio is shown in Table 2.
A wide variety of performance metrics are commonly
used to assess PPI prediction methods. These are sum-
marized and computed in Table 3 below.
This leave-one-out test was repeated with all homologs
removed from our human dataset as in [24]. This re-
duced our protein sequence set from 22,513 to 14,867
and our experimentally verified human PPI set from
41,678 to 19,588 pairs. Removing homologs at the 40%
identity level effectively removes all protein isoforms
from our LOO performance assessment. This leads to a
conservative estimate of performance as not removing
the homologs could potentially inflate the reported stat-
istical performance figures [23,24]. As can be seen in the
figure in Additional file 1 (pink line), the recall of our
method is slightly reduced when homologous proteins
are removed from our dataset, however if we adjust our
decision threshold to maintain a recall of 23%, we still
achieve a precision of 69.1%.
All-against-all (pair-wise) scan of the human proteome
After three months of 24/7 computation on the 50 fully
dedicated nodes of the large cluster (plus additional
computation on the medium cluster), MP-PIPE com-
pleted the scan of the human proteome. With the
chosen operating point as described in the previous sec-
tion, MP-PIPE predicted 172,132 protein interactions.
Table 2 The ratio-adjusted confusion matrix the leave-
one-out cross-validation tests used to determine the
prediction accuracy of MP-PIPE
Known
interacting
pairs
Assumed
non-interacting
pairs
Total
Predicted to Interact 9,586 (TP) 2084 (FP) 11,670
Predicted not to Interact 32,092 (FN) 4,165,716 (TN) 4,197,808
Total 41,678 4,167,800 4,209,478
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interactions have never been reported previously. Given
that 41,678 human protein interactions are known (pre-
viously reported) and were included in the MP-PIPE
database and would therefore be predicted to interact,
MP-PIPE has potentially more than quadrupled our
knowledge of the human interaction network. At the
chosen operating point, MP-PIPE data covers more than
one fifth of the estimated human PPI landscape. In
comparison, Elefsinioti et al. [13] have examined 2% of
the interactome while others have examined just over
7% [12] and 12.4% [14] of the total interactome. The list
of the reported interactions is found in the table in
Additional file 2. The list is ordered according to PIPE
score, where higher values represent higher confidence
levels for an interaction. Distribution of run time for
different human protein pairs is illustrated in Figure 1A.
The length of the query proteins does not appear to
correlate with runtime (data not shown). The analysis
performed on MP-PIPE’s predicted 172,132 interactions
throughout the rest of this study will cover both the
known 41,678 and novel 132,710 interactions, unless
stated otherwise.
Besides leave one out cross-validation, another stand-
ard method for evaluating PPIs is to check whether the
proteins pairs predicted to interact are co-located within
the same cellular component, have the same molecular
function, are involved in the same biological process orTable 3 Statistical performance metrics for MP-PIPE based
on true negatives (TN), true positives (TP), false negatives
(FN), and false positives (FP) seen in the leave-one-out
cross-validation tests, corrected to use a positive: negative
ratio of 1:100
Statistical measure Definition Value
Specificity (True Negative Rate) TNFPþTN 0.9995
Sensitivity/Recall
(True Positive Rate)
TP
TPþFN 0.2300
Precision TPTPþFP 0.8214
Accuracy TPþTNTPþFPþFNþTN 0.9919
F1 Score 2TP2TPþFPþFN 0.3594
Matthews correlation coefficient TPxTN−FPxFNﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
TPþFPð Þ TPþFNð Þ TNþFPð Þ TNþFNð Þ
p 0.4322have a common third party interacting partner. The
results of this analysis are shown in Table 4 and Figure 2.
The overall profiles for the predicted interacting pairs
that have not been detected before, on the basis of cellu-
lar localization, process and function resembles that of
previously reported pairs (Figure 2). Certain differences
however are noticeable. For example, a new association
for “metal ion binding” and “transcription” is observed
for the predicted interactions and not for those that have
been previously reported (Figure 2B). Similarly, there is
a strong association between “immune response” and
“signal transduction” for the predicted interactions
(Figure 2C). As indicated in Table 4, the percentage of
predicted interacting protein pairs that have similar
function, occur in the same cellular component and par-
ticipate in the same cellular process is 20.6%, which is
consistent with the percentage for previously reported
protein pairs (35.0%). In contrast, only 0.8% of randomly
selected protein pairs share these three traits. It is im-
portant to note that the PIPE algorithm has no previous
knowledge of the protein location, molecular function of
proteins, or the biological processes in which they are
involved. Such an association for protein pairs predicted
by MP-PIPE further highlights the ability of this method
to predict interactions that can be supported by inde-
pendent parameters. Such contextual information can
also be used to assign an independent degree of confi-
dence for PPI predictions. For example, higher confi-
dence might be assumed for a protein pair where both
proteins occur in the same location and share the same
GO term for a cellular process. This information is pre-
sented in the table in Additional file 2 and can be used
to form a priority list of interactions for further bio-
logical analysis.
In addition to the above cross-validation, we inde-
pendently evaluated the competence of our predictions
by evaluating experimental data gathered using the
Lentivirus-delivered, Gateway-compatible affinity Tag-
ging System coupled with Mass Spectrometry (LGTS-
MS) approach that has been recently developed for the
identification of PPIs in mammalian cell lines [28]. The
LGTS system uses a versatile affinity (VA)-tag con-
structed in-frame with a Gateway cassette consisting of
3x Flag, 6x His, and 2x Streptactin (Strep) epitopes, with
Flag and His separated by dual TEV protease cleavage
sites for efficient affinity purification [28]. Using this
approach, we stably expressed four (CBX1 (P83916),
RNF2 (Q99496), H2AFX (P16104), and RBBP4 (Q09028 ))
C-terminal affinity tagged chromatin-related proteins in
human embryonic kidney (HEK) 293 cells that play an
important role in the epigenetic control of chromatin
structure and gene expression, transcriptional repression,
nucleosome remodeling, and chromatin assembly [29-33]
(Figure 3A). These tagged proteins were affinity-purified
Table 4 Percentages of Homo sapiens pairs in which both partners share the same GO SLIM annotation as well as third
party interactions
Derived from GO annotation Third party
interactionCellular
component (CC)
Molecular
function (MF)
Biological
process (BP)
CC & MF & BP
(a) Random H. sapiens pairs 19.7% 8.2% 2.8% 0.8% 0.4%
(b) Previously reported H. sapiens interactions 77.2% 64.4% 46.6% 35.0% 59.2%
(c) Predicted H. sapiens interactions identified in this study 64.1%* 43.9%* 30.8%* 20.6%* 23.9%*
*P-value <1e-16.
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teins were identified by tandem mass spectrometry.
As expected, we recovered both the bait and several
well-known interacting protein partners, such as the
interaction between the tagged histone binding protein,
RBBP4 (Q09028) and subunits of the core histone deace-
tylase complex (HDAC1 (Q13547) and RBBP7 (Q16576)),
confirming the overall efficacy of the protein purification
procedure employed in the identification of co-purifying
interacting proteins (Figure 3B; Additional file 3). Consist-
ent with the biological expectation, these co-purifying pro-
teins were enriched for more chromatin related functions
such as chromatin organization, binding and assembly;
nucleosome assembly; histone ubiquitination; and tran-
scriptional regulation. Examples of functional clusters
identified through the LGTS-MS based method are shown
in Figure 3B. To investigate MP-PIPE’s ability to explain
the observed LGTS-MS data, we computed the precision
and recall of MP-PIPE predicted interactions. This is sum-
marized in Table 5 where reachable proteins are defined
as those proteins that interact directly or through one or
two intermediary proteins. This accounts for the fact that
a bait and prey observed to co-purify in a LGTS-MS
experiment may, in fact, interact indirectly through one or
more intermediary proteins. For the four baits, previously
known PPI interactions (high confidence literature data)
can only explain on average 10.89% (recall) of the co-
purifying proteins (prey). Using MP-PIPE predictions
increases our recall by ~3-fold (29.31%) while maintaining
comparable precisions.
Our predicted interactions appear to have a wide
coverage of the human proteome. For instance, of the
22,513 human potential open reading frames included in
this study, 11,194 were found in our prediction list (i.e.,
form at least one interaction) for a coverage of approxi-
mately 50%. Since a total of 172,132 interactions were
predicted, on average there appears to be approximately
15 interactions for each protein found in the prediction
list. As illustrated in Figure 4, approximately 32% of the
predicted interactions occur in the nucleus, followed by
21% in the cytoplasm. In fact, the distribution of the
identified interactions is very consistent with those of
the previously reported (known) ones. This distribution
is also in accordance with the previously reported PPIdistribution in S. cerevisiae [6]. Of interest are mem-
brane proteins, which although not readily amenable to
experimental assays, received good coverage using MP-
PIPE. The full range of biological processes and molecu-
lar functions is also well covered (Additional file 4). On
the basis of expression level (obtained from ArrayEx-
press EMBL-EBI), 66.26% and 68.99% of highly and low
expressed proteins, respectively, also appear in the list of
PPIs. We also examined the interactions for fibroblast
growth factors (FGFs) and cyclin-dependent kinases
(CDKs) with fibroblast growth factor receptors (FGFRs)
and regulatory inhibitors and activators of cyclin-dependent
kinases, respectively. These represent examples of proteins
that share high similarity in primary sequence and molecu-
lar function, yet have differences in substrate specificity
and regulatory factors. Shown in the table in Additional
file 5 there are clear differences in interacting partners for
different members of FGF and CDK proteins. Altogether
these observations suggest that our prediction method
appears to be inclusive and specific, and is amenable to
diverse set of proteins presenting a good coverage of the
proteome.
Network-wide analysis of hubs and betweenness
centrality
In a PPI network, the degree of interaction for a target
protein is believed to be a good indicator for the bio-
logical importance of that protein within the system
[34,35]. Removal of the highly connected proteins or
“hubs” appears to have a more profound effect on the
integrity of the network by reducing the size of the
largest connected module, than removal of random pro-
teins [36]. We studied the top 10, 25 and 50 hubs with
the highest number of interactions within our predicted
PPI network, and observed very high enrichment for
proteins that affect transcription and gene expression
(Table 6). Transcription factors mediate differential gen-
etic programming and hence are of central importance
in developmental biology [37], responses to stimuli [38],
disease progression [39], etc. Betweenness centrality is
another topological feature of a network and evaluates
the number of shortest paths that pass through a given
node [40]. Therefore, high betweenness centrality for a
protein represents the relative number of shortest paths
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Figure 2 (See legend on next page.)
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(See figure on previous page.)
Figure 2 Distribution of the interacting protein pairs on the basis of subcellular localization (A), molecular function (B) and cellular
process (C) for both previously detected interactions and interactions unique to this study normalized by the number of possible pairs
with both GO terms. The overall co-occurrence (association) for pairs that were previously not reported is similar to that of previously reported
interactions. The observed enrichment for certain categories within predicted interactions may represent new association or cross-communication. For
example, in panel B, a co-occurrence (association) for “metal ion binding” and “transcription” is observed for predictions that were not previously
reported. Similarly, in panel C, “immune response” and “signal transduction” have a more profound association among the predicted interacting pairs
in this study.
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http://www.biomedcentral.com/1471-2105/15/383that are associated with that protein. Consequently, pro-
teins with high betweenness centrality are thought to
play a central role in the cross-talk and communication
between interconnected modules of a network by form-
ing “traffic bottlenecks” for communication [41]. We
evaluated the top 10, 25 and 50 proteins with highest be-
tweenness centrality values within our predicted network.
Consistent with the expected role of these proteins in
signaling, we observed (Table 3) that they were highly
enriched for proteins involved in intracellular communica-
tion (kinase activity and signaling), or for which communi-
cation is of central importance (regulation of cell death).
Centrality measurements are often used to predict the
possible involvement of a protein in disease etiology and
progression. Some studies suggest that hubs are likely
enriched for disease proteins, whereas others incline
towards betweenness centrality as a better indicator
[42-46]. We therefore examined a possible relationship
between the top 500 proteins with the highest degrees ofP62
30
60
45
15
Q99496P83916 Q09028P16104
kDa1 2 1 2 1 21 2
A B
Figure 3 Affinity purification experiments using P83916 (CBX1), Q994
(A) Immunoblot confirming the expression of the indicated FLAG-tagged c
independent FLAG tag constructs of each chromatin related protein was con
and to uncover highly reproducible interactions. Molecular masses (kDa) of m
clusters identified from affinity purification data (light gray) and expanded by
(ellipses). Blue nodes represent co-purifying proteins identified through affinity
clusters through MP-PIPE predictions. Red dashed edges (lines) represent prev
data and green solid edges represent novel (not previously reported) MP-PIPEcentrality (hub and betweenness centrality) and their re-
ported involvement in disease progression. As illustrated
in Figure 5, both hub and betweenness centralities ap-
pear to be good indicators for disease proteins. However,
betweenness centrality appeared to have a better correl-
ation than hubs for disease proteins. A ranked list of top
500 proteins according to their centrality measures is
reported in Additional file 6 (hubs) and the table in
Additional file 7 (betweenness centrality). We note that
the relationship between connectivity (with hubs having
a higher connectivity) and disease is dependent on a var-
iety of factors, particularly gene essentiality [45], which
we have not investigated here in depth.
The usefulness of the predicted interactions in biological
investigations
Our computationally predicted interactome represents a
comprehensive all-to-all interaction network in humans.
This network generates a wide range of testable hypothesesP16104
Q99496
Nucleosome Assembly
Histone Monoubiquitination
Q99733
Q96QV6 Q16576
P20671
Q09028P04908
807
O60264
Transcription Repression
P83916
P45973
Q13547 Q92769
Q6W2J9
O60264
P27695
P16104
Q09028
Q16576
Q14839
Histone Deacetylation
Q13547
Q12873
O60264
P51531
P51532 P83916
Q13185
Q13263
Q8IXK0
P35226
Q9HC52
Q06587Q9BYE7
Q16695
96 (RNF2), P16104 (H2AFX), and Q09028 (RBBP4) as baits.
hromatin proteins using antibody against the 3X FLAG epitope. Two
structed for affinity purifications to eliminate background contaminants
arker proteins by SDS-PAGE are indicated. (B) Representative functional
MP-PIPE predictions (dark gray). Tagged-baits are shown by yellow nodes
purification. Purple nodes represent proteins added to the functional
iously reported binary interactions identified in literature experimental
binary interaction predictions.
Table 5 Overlap of co-purifying proteins identified through LGTS-MS with previously reported (known) interactions
and MP-PIPE predictions
Reachable proteins Prey reached Recall1 Precision2
Bait # of prey Known MP-PIPE Known MP-PIPE Known MP-PIPE Known MP-PIPE
Q09028 301 112 201 56 99 18.60% 32.89% 50.00% 49.25%
P83916 474 91 244 59 178 12.45% 37.55% 64.84% 72.95%
P16104 209 39 207 11 82 5.26% 39.23% 28.21% 39.61%
Q99496 292 16 24 13 15 4.45% 5.14% 81.25% 62.50%
Total 1276 258 676 139 374 10.89% 29.31% 53.88% 55.33%
1Recall calculated as reached/# of prey.
2Precision calculated as reached/reachable.
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http://www.biomedcentral.com/1471-2105/15/383concerning biological processes, and informs our under-
standing of the overall architecture of cellular function.
Here, we demonstrate the usefulness of this new predicted
interactome through prediction of gene functions, experi-
mental verifications and analysis of putative protein
complexes.
Using the predicted human protein interaction network
to assign breast cancer proteins
Breast cancer is the most commonly diagnosed form of
cancer among women [47]. BRCA1 and to some extent
BRCA2 are the two key genes associated with breast
cancer progression. Breast cancer susceptibility has been
related to a mutation of BRCA1 [48]. Carriers of BRCA1N
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Figure 4 Number (A) and percentage (B) of co-localized interacting p
with those reported in this study only. Note that since proteins can have
and can be counted more than once.(and some BRCA2) mutations have a 50-80% increased
risk of developing breast cancer [49]. It is estimated that
10% of western women fall in this category [47]. While
the tumor suppression property of BRCA1 is well inves-
tigated, the molecular mechanism of its activity in tumor
prevention is not fully understood [50]. Figure 6 illus-
trates a brief overview of the breast cancer pathway
where BRCA1 plays a central role. As illustrated, (see
Figure 6) BRCA1 is directly associated with several cellular
processes including chromatin remodeling, DNA damage
checkpoint activation, DNA damage sensing, and DNA
double stranded break (DSBs) repair. BRCA1 plays an
essential role in delaying cell cycle progression by its DNA
damage checkpoint activity. ATM phosphorylation of p53,P
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Previously detected
This study
airs by GO components in previously reported data compared
multiple tags, interacting pairs can be co-localized in several components
Table 6 Enrichment of biological process for proteins with highest Hub Degree (Hubs) or Betweeness Centrality (B.C.)
measurements (Top 10, Top 25, and Top 50)
Biological process Top 10 Top 25 Top 50
# prot P-value # prot P-value # prot P-value
Hubs Transcription regulation 7 2.26E-06 16 3.15E-10 28 1.93E-14
Regulation of gene expression 7 4.88E-06 16 1.69E-09 29 2.82E-14
B.C. Protein kinase activity 2 5.99E-02 6 1.01E-07 20 8.61E-18
Regulation of cell death 3 3.96E-05 11 7.60E-09 19 1.82E-12
Signaling 4 5.49E-05 13 5.90E-09 33 7.45E-12
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http://www.biomedcentral.com/1471-2105/15/383a tumor suppressor protein, is mediated by BRCA1 and, in
the presence of DNA damage, delays or arrests G1/S tran-
sition [51]. BRCA1 is important during S phase and G2/M
checkpoint activation through its regulation of kinase ac-
tivity of Chk1 [52]. Upon DNA damage, H2AX is phos-
phorylated by ATM and ATR and recruits MDC and
RNF8 to the site of the damage. Subsequently, BRCA1 is
translocated to the site of damage by ubiquitination of
H2A through RNF8 and Ubc13 [47] and interacts with the
Mre11/Rad50/Nbs (MRN) complex that is involved in
double stranded DNA break repair [53]. Examining the
proteins involved in the breast cancer pathway for PPIs,
MP-PIPE predicted over 3,000 interactions, 424 of which
(161 and 263 known and novel interactions, respectively)
directly involve BRCA1 (P38398). Studying these interac-
tions can expand our current understanding of the breast
cancer pathway. A number of interesting factors were
found to form novel interactions with multiple proteins
associated with the breast cancer pathway, including
CDK3, AURKB, and SMC1b (see Figure 6).0
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Figure 5 Comparing the number of disease-associated proteins with
highest betweenness centrality appear to be more enriched for disease proCDK3 is a cyclin-dependent kinase that functions in
cell cycle progression and mitosis, and plays an essential
role in G1/S transition through its activation of the E2F
transcription factor family and G0/G1 transition by Rb
phosphorylation [54]. E2F and Rb play a regulatory role
in the transcription of BRCA1 [55], connecting CDK3 to
BRCA1. In further agreement with the observed interac-
tions, CDK3 has high expression levels in cancer cells
and participates in cell proliferation and transformation
by enhancement of ATF1 activity, a gene that physically
interacts with BRCA1 ([56,57]). Furthermore, both BRCA1
and CDK3 are involved in cell cycle transition, further
supporting a potential role for CDK3 in breast cancer.
AURKB has several functions during mitosis, including
spindle assembly, chromosome segregation, and cytokin-
esis [58]. AURKB has high sequence similarity with
AURKA, another protein of the Aurora kinase family,
however they are reported to differ functionally from
each other during mitosis [59]. It is shown that BRCA1
may be phosphorylated by AURKA, resulting in impairedP
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Figure 6 Schematic diagram of breast cancer pathway. BRCA1 plays a central role in breast cancer by connecting DNA damage and
chromatin remodeling to downstream processes such as cell cycle progression and DNA repair. Black lines (edges) represent biochemical
pathways, red and green edges are novel and known PPIs, respectively. Ovals and clouds represent proteins and protein complexes, respectively.
Red ovals represent novel proteins that are associated with breast cancer pathway on the basis of the predicted interactions they form.
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http://www.biomedcentral.com/1471-2105/15/383function of BRCA1 in G2/M transition [60]. AURKB has a
single reported interaction within breast cancer pathway
through BRCC complex [61]. The interactions identified
here add credibility to the involvement of this protein in
breast cancer pathway.
SMC1B is a meiosis-specific protein involved in chro-
mosome segregation during anaphase, synapsis, and
recombination [62]. SMC1B is also part of the cohesin
complex, which includes SMC1, SMC3, RAD21 and sev-
eral other proteins [63]. The cohesin complex plays a
role in several cellular processes such as DNA repair,
gene expression regulation and chromosome segregation
([63,64]). Recent studies showed that several subunits of
the cohesin complex are also important in DNA damage
response [64]. In addition, SMC1b has been linked to
neck and head cancer [65], further supporting a role for
this protein in cancer.
We also examined the PPI network for mutations
associated with resistance to breast cancer therapeutics
doxorubicin and Trastuzumab. Individual mutant pro-
teins were analyzed against the human proteome (one-
against-all) for their PPIs at a recall of 23% at a precisionof 82.1%. In this way, 5 personalized human PPI net-
works were predicted, each differing by a mutation in
one gene only. The 5 PPI profiles were compared to that
of their corresponding control networks. The list of
these mutants is found in the table in Additional file 8.
Four mutations, P04637a, P04637b, P04637c and P04637d,
in p53 (P04637) protein have been linked to resistance to
the chemotherapeutic breast cancer drug, doxorubicin
[66]. The PPI profile for P04637b and P04637d was identi-
cal to that of the wild type. However, the other two mu-
tants showed some differences. For example, P04626a and
P04626c lost their interactions with the nuclear transcrip-
tion factor Y, NFYC (Q13952) and the ubiquitin conjugat-
ing enzyme E2 L3 (P68036) involved in nuclear hormone
receptors transcriptional activity, among others. Similarly,
a truncated form of HER2 (P04626) is responsible for re-
sistance against HER2-targeted breast cancer therapeutics
such as Trastuzumab [67]. We observed that truncated-
HER2 lost several PPIs including an interaction with a
G-protein signaling RGS8 (P57771) which functions as an
inhibitor of signal transduction, and an interaction with an
early growth response protein ERG1 (P18146) involved in
Schoenrock et al. BMC Bioinformatics 2014, 15:383 Page 12 of 22
http://www.biomedcentral.com/1471-2105/15/383cell differentiation. Of interest, the truncated HER2 formed
a new interaction with the tumor suppressor p53 protein.
A possible explanation for this novel interaction for the
truncated HER2 could be that segments of the deleted re-
gion might have physically hindered the availability of the
region responsible for an interaction with p53 in the wild
type form.
Identification of novel molecular markers for seasonal
allergic rhinitis
Glucocorticoids (GCs) have a key role in the treatment
of patients with seasonal allergic rhinitis (SAR) and
other allergic disorders [68]. Because of this and difficul-
ties in evaluating treatment response based on clinical
signs and symptoms, there is a need for protein markers
to monitor that response. The identification of such
markers is complicated by the involvement of a large
number of inflammatory proteins in SAR [69]. We hy-
pothesized that novel biomarkers could be identified
among proteins predicted to interact with proteins belong-
ing to known inflammatory pathways in SAR including
the acute phase response pathway, complement signaling
pathway and glucocorticoids receptor pathway [70,71].
Proteins from the acute phase response pathway, com-
plement signaling pathway and glucocorticoids receptor
pathway were extracted from the Ingenuity pathway ana-
lysis (IPA) software. Interactors of these proteins were
selected from our predicted human PPI network. We
included secreted, membrane and cytoplasmic proteins,
but excluded nuclear proteins. We prioritized candidate
biomarkers based on their number of known and pre-
dicted interactions with proteins known to be involved
in SAR-associated responses. Next, we focused on pro-
teins with a high number of predicted interactions.
From the literature we extracted 191 proteins that
belong to the acute phase response pathway, comple-
ment pathway, and glucocorticoids receptor pathway
(Additional file 9). These proteins formed the known set
of SAR-associated proteins (SARp). From our predictedFigure 7 Analysis of candidate proteins with ELISA. Proteins were analy
treatment. Pre, patients before GC treatment; Post, patients after GC treatm
treatment with P-values of <0.001 and <0.05, respectively.human PPIs, the proteins that interacted with SARp
were determined. A total of 3334 proteins were found to
interact with one or more SARp. We prioritized five new
proteins with a high number of total and predicted inter-
actions to SARp as candidate biomarkers, namely PRB1,
PRB2, SFN, LYN and Akt2. Using ELISA, we analyzed
these candidates in nasal fluid from 40 patients with
SAR before and after GC treatment. This study repre-
sented protein expression analysis for 400 samples (5
proteins, before and after GC treatment, in 40 patients).
It was observed that after GC treatment LYN concen-
tration increased from 396.1 ± 30.5 pg/mL to 537.7 ±
35.5 pg/mL (P-value <0.001). PRB1 decreased from 16.3 ±
7.0 ug/mL to 8.5 ± 2.1 ug/mL (P-value <0.05) (Figure 7).
PRB2 was not differentially expressed before and after
treatment, and SFN and Akt2 were not detectable in most
samples. Differential protein expression for LYN and
PRB1 provides a good evidence for the possibility of using
these proteins as novel molecular markers for SAR.
Altogether, the data presented here illustrates the suitabil-
ity of the predicted PPIs for identifying potential new
molecular markers for human conditions.
The proteome-wide PPI network can identify translation
genes
The process of protein synthesis or translation is the
process by which the genetic message embedded in
mRNAs is sequentially read and converted into polypep-
tide sequences. Due to its absolute requirement for the
survival of a cell, this process has remained highly con-
served through the course of evolution. Our predicted
interactome included novel interactions for five human
proteins Q96DG6 (CMBL), Q08AM6 (VAC14), P23511
(NFYA), Q9UKR5 (ERG28) and P48735 (IDH2) with
proteins known to play roles in the process of transla-
tion. To study the involvement of these five proteins in
translation, we subjected their corresponding yeast
homologs (AIM2, VAC14, HAP2, ERG28 and LYS12,
respectively) to experimental analysis. First, we examinedzed in nasal fluid from 40 patients with SAR before and after GC
ent. LYN and PRB1 were differentially expressed before and after GC
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http://www.biomedcentral.com/1471-2105/15/383the effect of their deletion on stop-codon read-through
using three different expression plasmids, pUKC817,
pUKC818 and pUKC819 that carry premature stop
codons UAA, UGA and UAG, respectively, within a β-
galactosidase reporter gene. As evident from an increase
in relative β-galactosidase activity shown in Figure 8A, the
deletion of HAP2, ERG28 and LYS12 significantly altered
the ability of ribosomes to detect all three stop codons. To
confirm that the observed elevation of β-galactosidase was
at the translation level, mRNA content of β-galactosidase
was measured. No difference between relative content of
β-galactosidase mRNAs was observed in deletion and
control strains (Figure 8B).
We then further investigated the involvement of
HAP2, ERG28 and LYS12 in translation by subjecting
their deletion mutants to drugs that affect translation.
hap2Δ, erg28Δ and lys12Δ showed altered levels of sensi-
tivity to streptomycin and cycloheximide (Figure 8C).
Next, translation efficiency (rate) was measured using an0
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Figure 8 Novel involvement of HAP2, ERG28 and LYS12 in translation
the activity of the mutant strains carrying different stop-codon read throug
codon) in the wild type strain. B) The relative mRNA level is determined by
premature stop-codon expression cassettes to those in the wild type. C) In
inhibitory drugs. Sensitivity of the wild type strain was used as a point of re
respect to that for the wild type strain. hap2Δ, lys12Δ, and erg28Δ show inc
D) Effect of gene deletions on translation efficiency. Relative translation eff
promoter in LacZ expression cassette normalized to mRNA content. Valuesinducible LacZ gene cassette on a p416 plasmid [72].
Deletion mutants for ERG28 and LYS12 had a drastic
reduction in the rate of induced LacZ synthesis further
linking ERG28 and LYS12 to translation (Figure 8D).
Interestingly ERG28 is a well-characterized protein in-
volved in ergosterol biosynthetic pathway, the relation of
which to translation is not readily expected. However, in
agreement with a link to translation, ERG28 was previ-
ously shown to physically interact with a polysome asso-
ciated mRNA binding protein SLF1 [73], and a putative
RNA helicase SPB4 that sediments with 66S pre-
ribosomes [74]. Further, ERG28 is localized to ER mem-
branes and a general link between sterol biosynthesis
and translation has previously been proposed [75].
Identification of protein complexes within the human
interaction network
Protein complexes can be defined as a group of proteins
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reased sensitivity to one or both streptomycin and/or cycloheximide.
iciency was measured using p416 plasmid containing Gal-inducible
are related to translation efficiency of the control strain set at 1.0.
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http://www.biomedcentral.com/1471-2105/15/383Paracliques [76-78] can be computationally identified as
a sub group of proteins within the interaction network
with high degree of interconnectivity and may define
putative complexes. Given the size of the human PPI
network, prediction of paracliques requires advanced
computational approaches to complete a thorough ana-
lysis within a reasonable timeframe. We have applied a
novel graph theoretic approach to automatically identify
paracliques within the network (see Methods for details).
Our analysis led to a number of interesting predictions.
For each paraclique, a statistical analysis of gene ontol-
ogy (GO) term enrichment was performed. The table in
Additional file 10 lists the top GO term for each paracli-
que along with a P-value for the observed enrichment.
For example, Paraclique 1359 is a complex of six pro-
teins with 13 interactions (Additional file 11: Figure A).
O00151 (PDLIM1) is a cytoskeletal protein that acts as
an adapter to bridge other proteins (like kinases) to the
cytoskeleton. P20929 (NEB) is a muscle protein involved
in maintaining the structural integrity of sarcomeres and
membranes associated with the myofibrils (F-actin
stabilization). The rest of the members (P08670 (VIM),
P14136 (GFAP), P17661 (DES) and P41219 (PRPH)) are
intermediated filament proteins. On the basis of GO en-
richment (P-value 6.5E-07), one may conclude that the
activity of this complex is associated with cytoskeleton
and structural integrity of the cell.
Paraclique 1409 is a complex of six proteins with 14 in-
teractions (Additional file 11: Figure B). Q02246 (CNTN2)
is involved in cell adhesion and the remaining proteins
(O94779 (CNTN5), Q02246 (CNTN2), Q12860 (CNTN1),
Q8IWV2 (CNTN4), Q9P232 (CNTN3), and Q9UQ52
(CNTN6)) are involved in cell surface interaction during
nervous system development. On the basis of GO enrich-
ment, we can assign this complex to cell adhesion (P-value
2.2E-10).
Paraclique 2164 is a complex of five proteins with 10
interactions (Additional file 11: Figure C). Three of its
members (P32298 (GRK4), P34947 (GRK5) and P43250
(GRK6)) are G protein-coupled receptor kinase and the
remaining two (Q9NP86 (CABP5) and Q9NZU8 (CABP1))
are calcium-binding proteins. Considering the fact that
biological interaction between G-protein coupled receptor
and calcium-binding proteins has been widely reported
and seems essential in signaling pathways, one may con-
clude that this complex plays a role in G-protein coupled
signaling pathway, a claim which is supported by enriched
Gene Ontology term (P-value 3.75E-08).
Limitations and future work
While MP-PIPE represents a significant step forward to-
wards computing a complete human interactome, there
remain a number of limitations which lead us to future
work. In order to operate at a reasonable precision rate,we have tuned our decision thresholds to be extremely
conservative, resulting in a limited sensitivity of 23%. Fu-
ture work will examine ways to continue to increase sen-
sitivity/recall without sacrificing our false positive rate.
Where MP-PIPE has advantage over structure-based
methods is in coverage: MP-PIPE requires only sequence
as input and is therefore applicable to all protein pairs.
However, in future work we will examine ways to
capitalize on the rich information encoded in protein
structure when such inputs are available. At present, this
represents only a small fraction of protein pairs, how-
ever, this proportion is expected to grow with ongoing
large-scale protein structure determination initiatives. As
with all computational methods, another potential limi-
tation in prediction accuracy is the quality of input data
used to train MP-PIPE. As more experimental data of
higher quality becomes available, we expect MP-PIPE to
also become more accurate. Lastly, we are continuing to
apply parallelization and algorithmic optimizations to MP-
PIPE to further reduce runtimes for whole-proteome
scans. This will be critical if we are to investigate large
numbers of organisms for comparative studies, or if we
wish to compute personalized interactomes, accounting
for the multitude of genetic variations that make each
person’s interactome unique.
Conclusions
In this study, we present a comprehensive pair wise
analysis and prediction of the entire human PPI network
using the principles of short co-occurring polypeptide
regions as mediators of PPIs. Through this massive com-
putational analysis, we predict approximately 170,000
PPIs, of which 140,000 have not been reported previously.
The distribution of the novel PPIs on the basis of sub-
cellular localization, molecular function and biological
process are very similar to those of previously reported
interactions, highlighting the reliability of our predictions.
Moreover, we demonstrate that MP-PIPE predictions can
effectively explain experimentally observed LGTS-MS
interaction data (recall 29.31%, precision 55.33%). Our
predictions are useful for understanding cellular biology as
a whole, with approximately 8,000 protein complexes in
our inferred interaction network. Furthermore, specific
processes can be successfully interrogated using our new
predictions: on the basis of inferred interactions we pre-
dict and experimentally confirm novel functions for pro-
teins involved in translation, and identify new molecular
markers for seasonal allergic rhinitis. Our analysis high-
lights the usefulness of the predicted PPIs for functional
analysis of the human proteome. The speed associated
with this approach sets the path for investigating the PPI
map for individual humans in a timely fashion. Personal
(specific to an individual) PPI maps may improve our
knowledge of network and personalized medicine.
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Sequential PIPE algorithm
For a given organism (e.g. S. cerevisiae, C. elegans, or hu-
man), the PIPE algorithm relies on a database of known
and experimentally verified protein interactions. For
example, for the 22,513 human potential open reading
frames included in the current study, only 41,678 high
confidence interactions are known (out of 253,406,328
possible protein pairs). Since experimental verification
can have large numbers of false positives (up to 40%, see
e.g. [19]), the PIPE database is carefully constructed to
avoid false data and stores only protein interactions that
have been independently verified by multiple experi-
ments. The database represents an interaction graph G
where every protein corresponds to a vertex in G and
every interaction between two proteins X and Y is repre-
sented as an edge between X and Y in G. The remainder
of this section outlines how, for a given pair (A, B) of
query proteins, our PIPE method predicts whether or
not A and B interact.
In the first step of the PIPE algorithm, protein A is
split up into overlapping fragments of size w. This can
be thought of using a sliding window of size w across
protein A. For each fragment ai of A, where 0 < = i < = |A| -w +1, we search for fragments "similar" to ai in every pro-
tein in graph G. A sliding window of size w is again used
on each protein in G, and each of the resulting protein
fragments is compared to ai. For each protein that con-
tains a fragment similar to ai, all of that protein's neigh-
bors in G are added to a list R. To determine whether two
protein fragments are similar, a score is generated with the
use of the PAM120 substitution matrix. If the similarity
score is above a tuneable threshold then the fragments are
said to be similar or to “match” (see pseudocode below).
In the next step of the PIPE algorithm, protein B is split
into overlapping fragments bj of size w (0 < = j < = |B| -
w +1) and these fragment are compared to all (size w)
fragments of all proteins in the list R produced in the pre-
vious step. We then create a result matrix H of size n x m,
where n = |A| and m= |B| and initialize it to contain
zeroes. For a given fragment ai of A, every time a protein
fragment bj of B is similar to a fragment of a protein Y in
R, the cell value at position (i, j) in the result matrix is
incremented. The result matrix indicates how many times
a pair (ai, bj) of fragments co-occurs in protein pairs that
are known to interact. It is based on this matrix that the
query proteins are predicted to interact or not. The follow-
ing explains the basics of the algorithm in pseudocode:A modified median filter, which simply sets a cell’s
value to 1 if most of the neighbouring cells are greater
than zero and zero otherwise, is applied and the two
query proteins were predicted to interact if the average
cell value was above a set threshold. By varying this
threshold, a range of precision-recall values may be ob-
tained (see Additional file 1). Note that throughout this
paper, for our analysis a prevalence of 1 PPI per 100 pro-
tein pairs is consistently assumed for our results, as well
as for comparison to other results as was done in [24].
Recall measures the proportion of true interactions that
will be detected. Precision measures the proportion of pre-
dicted interactions that correspond to true interactions.For our leave-one-out cross-validation experiments (as de-
scribed in the ‘Verification of MP-PIPE Against Experi-
mental Data’ section), our 41,678 high confidence positive
PPIs are taken from BioGrid [25]. Random protein pairs
not previously reported to interact were used for our nega-
tive interaction data. This is considered to be a conserva-
tive approach when assessing prediction accuracy [26].
MP-PIPE overview
The MP-PIPE (massively parallel PIPE) system is a mas-
sively parallel, high throughput protein-protein inter-
action prediction engine and is the first system that is
capable of scanning the entire protein interaction network
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that goal, large numbers of concurrent PIPE instances
need to be executed on a large-scale parallel compute
cluster. This created two major challenges.
The first problem was the lack of scalability that made it
difficult for large numbers of PIPE instances to effectively
take advantage of all available computational resources
without massive load imbalances. This load-balancing
problem was not as significant in simpler organisms, such
as S. cerevisiae and C. elegans, but lead to a large amount
of unused resources when making predictions on more
complex organisms such as human. Interestingly, the
number of human proteins and protein pairs is not excep-
tional and simpler organisms such a C. elegans actually
have more proteins and protein pairs than human. How-
ever, the human protein interaction network has more
known interactions and a more complex structure. In par-
ticular, the calculation/prediction of these interactions is
considerably more time consuming. Previous PIPE experi-
ments for S. cerevisiae [19,22] and experiments for C.
elegans reported in [23] showed that PIPE can process
each individual protein pair within seconds. However, for
human proteins, the picture changes dramatically. The
running time for one individual protein pair can fluctuate
between less than a second and more than 12 hours. Hu-
man proteins have a much more complex structure that
appears to lead, in some cases, to a very large number of
fragment similarities found by PIPE. When trying to run
earlier versions of PIPE on human protein pairs, individual
PIPE instances would simply be given static lists of protein
pairs to make predictions on. Due to the wide variance of
processing time for human protein pairs, some PIPE
instances would finish very quickly while, by the end, there
may be a single PIPE instance working for hours on a
single protein pair while all of the other instances are idle.
The imbalance when processing human protein pairs was
so great that it resulted in more wasted resources than uti-
lized resources when processing batches of protein pairs.
To process a global scan of all human protein pairs, this
issue had to be overcome.
The second major issue facing concurrent PIPE in-
stances on a processor is inefficient usage of memory.
Typically the number of PIPE processes running on a
single machine is set to the number of compute cores
on that machine. For example, on a quad-core machine
there would typically be four PIPE processes running to
utilize the chip fully. If different PIPE processes were left
to work completely independently of each other, each
process would have to load its own copy of the inter-
action graph along with all the other PIPE data. For less
complex organisms this was not a major issue since the
amount of data loaded was relatively small but the com-
plexity of the human proteome translates into signifi-
cantly more data needed by PIPE. The memory needsfor a single PIPE instance for the human proteome
increased to such a degree that running as many PIPE
instances as compute cores can easily lead to program
crashes due to a lack of memory. This would imply that
processor cores would be left unused due to memory
limitations. To process a global scan of all human pro-
tein pairs, this issue had to be overcome.
The basic structure of MP-PIPE is a two-level master/
slave and all-slaves model. A single MP-PIPE scheduler
process is in charge of managing the main list of protein
pairs to be processed as well as reporting the results.
The MP-PIPE scheduler distributes work to several MP-
PIPE worker processes in packets. Each packet contains
a relatively small number of protein pairs. Each MP-
PIPE worker executes the PIPE algorithm on protein
pairs received from the MP-PIPE scheduler. By giving
each worker only a relatively small amount of work at a
time we ensure that if a worker does get stuck with
abnormally time consuming protein pairs, the other
workers will continue to work on their packets and,
when they finish, they will request more work from the
scheduler process and continue to work. This aspect of
the MP-PIPE’s architecture deals with the load imbal-
ance problem by ensuring that all PIPE processes are
working as long as there is still work to be done. It
should be noted however that if the packet size is too
small then the amount of communication between the
scheduler and worker processes will negatively impact
the running time of the system. It is therefore important
to balance the packet size between being too small (too
much communication overhead) and too large (too
much work imbalance).
To improve the memory efficiency, the second level of
MP-PIPES’s architecture uses an “all-slaves” model. Each
PIPE worker process consists of a number of parallel
threads, called worker threads, among which it distrib-
utes the protein pairs to be processed. The worker
threads of an MP-PIPE worker are to be executed on a
shared memory multi-core processor. The PIPE inter-
action graph and other necessary PIPE data require con-
siderable amounts of memory. For MP-PIPE, the data
stored at an MP-PIPE worker process was re-designed
to become a parallel data structure on which all worker
threads for that worker can operate concurrently. Much
care was taken to implement this as memory efficient as
possible so that a single shared copy fits into the main
memory of a processor node executing an MP-PIPE
worker. This allowed more threads to run simultan-
eously on a given processor node by reducing the overall
memory usage and solved the memory issues discussed.
The scheduler/worker part of MP-PIPE was imple-
mented using MPI (Message Passing Interface) and the
worker threads within each MP-PIPE worker were im-
plemented in OpenMP (http://openmp.org/).
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MP-PIPE evaluated all possible protein pairs in the
human proteome. Most of this work was performed on
the large Victoria Falls cluster, using the medium cluster
to offload some of the harder pairs (i.e. those pairs that
took longer than 12 hours). The following represents the
human proteome at the time that the MP-PIPE scan was
performed.
 Total number of human proteins: 22,513
 Total number of protein pairs to examine:
253,406,328
 Total number of known protein interactions: 41,678
 Total number of proteins with at least one known
interacting partner: 9,459
 Total number of proteins with no known interacting
partners: 13,054
 Largest number of known interactions partners for a
single protein: 265
 Average number of known interactions per protein:
3.70
 Average number of known interactions per protein
with at least one interaction: 8.81
The 22,513 human proteins used in this study are
made up of the union of Uniprot “confirmed” proteins
and proteins involved in physical interactions reported
in BioGRID, with no isoforms removed. The 41,678 pre-
viously reported interactions were obtained from Bio-
GRID, which is an amalgamation of several experimental
studies. The human proteome has almost seven times
more known interactions than the C. elegans proteome,
and the average human protein has more than double
the known interactions than a C. elegans protein.
Coupled with the fact that the human proteins are, on
average, longer than the C. elegans proteins, this signifi-
cantly increases the complexity of scanning the entire
human proteome. Furthermore, as outlined above, the
running time for one individual protein pair can fluctu-
ate between less than a second and more than 12 hours.
This creates an additional load-balancing problem as
discussed above. In fact, some individual protein pairs
required six days of computation.
On the Victoria Falls cluster, 50 nodes were used, each
with their own MP-PIPE worker process running 256
threads. This implies 12,800 parallel computational
threads running on 6,400 hardware-supported threads.
The number of threads per node was scaled down from
512 threads due to the fact that each individual thread
needed significantly more memory than in our tests. The
Victoria Falls cluster was used to process the vast major-
ity of protein pairs. The results presented in this paper
were obtained through three months of exclusive 24/7
use of the large Victoria Falls cluster. If one of its workerthreads got stuck with a protein pair that was running
more than 12 hours, that protein pair was off-loaded to
the medium cluster since its individual cores are more
powerful than a single Victoria Falls thread.Hubs and betweenness centrality
Protein interactions can be represented as an interaction
network, where the proteins are interactors (nodes) and
connections (interactions) are shown as edges. The
number of edges incident to one node is called the de-
gree of that node. Hubs are high degree nodes that inter-
act with many other proteins (nodes) through various
pathways [79]. To find the hubs in the human predicted
interaction graph, the proteins were sorted by their de-
gree in the network. Betweenness centrality is an im-
portant global property of networks. The betweenness
centrality of a node v is the ratio of the number of short-
est paths between a pair of nodes a and b on which v
lies and the total number of shortest paths between a
and b, summed over all possible pairs of nodes. These
measures were used to identify proteins of interest. The
betweenness centrality of a protein v is defined as vð Þ ¼
X
a≠v≠b
σab vð Þ
σab
, where σab(v) = # shortest paths from a to
b through v, σab = # shortest paths between a and b.Versatile affinity-tagging, purification, and protein
identification
The full length, sequence verified, non-mutated, Gateway-
compatible cDNA entry clones for the human chromatin-
related proteins (CBX1, RNF2, H2AFX, and RBBP4) were
obtained from Harvard PlasmidID. The HEK293 and
HEK293T cells were cultured in Dulbecco’s modified Ea-
gle’s medium with 10% fetal bovine serum and antibiotics
essentially as previously described [28,80]. The sequence-
verified clones were cloned into the lentiviral expression
vector essentially as previously described [28,80]. The
lentivirus-encoded tagged ORFs were transduced into
HEK293 cells, and the stably expressed cells were subse-
quently selected with puromycin at a concentration of
2 μg/ml for a minimum of 48 hours and expanded, essen-
tially as described previously [28,80]. The expression of
the tag in stable cells was subsequently confirmed by
Western blotting using anti-FLAG antibody against the
3X FLAG epitope. Affinity purification and sample pro-
cessing for protein identification by mass spectrometry
was performed essentially as previously described [28,80].
The high-confidence matches of the resulting MS/MS
spectra was mapped to the reference human protein se-
quences using the SEQUEST database search engine with
match quality evaluated using the STATQUEST algorithm
[81]. The identified co-purifying proteins were filtered out
at a confidence threshold at 90% with two or more
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affinity purified two times to rule out the non-specific
binding proteins, we averaged the peptide counts over the
replicates. Moreover, the co-purifying proteins that were
identified at 90% cut-off with one single peptide and the
most common background contaminants or proteins that
bound to the unrelated VA-tagged GFP samples in our
replicate purifications were filtered out to eliminate the
noise from the dataset.
The comparison of LGTS-MS results with the MP-
PIPE predicted and previously reported (known) interac-
tions was done by calculating the precision and recall on
the basis of LGTS-MS results representing real interac-
tions. To do this we filtered the MP-PIPE predictions
and known interactions to contain detectable proteins
(the set of all proteins seen in any of the LGTS-MS
experiments performed here). Reachable proteins were
defined as those proteins that interact directly with the
bait or indirectly through one or two intermediaries
within the sets of filtered interactions.
Yeast growth condition
Standard rich (YPD) and synthetic complete (SC) media
were used as a growth media [72]. To investigate trans-
lation inhibitory drugs (antibiotics) on growth rate of
yeast deletion mutants, streptomycin (40 mg/ml) was
added to SC media and cycloheximide (60 ng/ml) was
added to YPD media [72].
Drug sensitivity test
Yeast cells were grown in liquid YPD or SC media to
mid-log phase (48 hours) and diluted to a concentration
of 10−2 to 10−5 cells/20 μl. From each dilution, 20 μl was
spotted onto solid media containing translation inhibitory
drugs. Media with no antibiotics was used as a control. All
yeast cells were incubated at 30°C for 1–2 days [82].
Protein expression assay
Translation fidelity was measured using plasmids pUKC817,
pUKC818 and pUKC819, which carry premature stop
codons UAA, UGA and UAG in a β -galactosidase expres-
sion cassette [72,83]. Translation efficiency was assessed
using plasmid p416 (containing Gal-inducable LacZ ex-
pression cassette) as described by [72,84]. β-galactosidase
assay was performed using ONPG, O-nitrophenil-α-D-
galactopyranoside, as descibed by [84-86].
qRT-PCR
Total RNA was extracted using RNeasy Mini Kit (QIA-
GEN) according to manufacturer's instruction. To syn-
thesize cDNA, 33 μl of RNA in combination with 3 μl
poly T primer (random hexamer) was incubated for five
min at 70°C, and then cooled on ice for five min. 6 μl
RT-buffer, 15 μl dNTPs, and 3 μl RNaseI were added tothe mixture and incubated for five min at 37°C. 3 μl RT
enzyme was added to the mixture and incubated for an
additional 1 hour at 42°C followed by aa 10 min incuba-
tion at 70°C. qPCR amplification and detection was per-
formed on a Rotor Gene 3000 from Corbett Research. A
final mixture of 2.4 μl H2O, 2.4 μl 10X PCR buffer,
1,25 μl dNTPs(4 mM), 1.25 μl MgCl2, 2 μl SYBR Green
(1/4000), 7.6 μl primer mix (1 mM) and 3 μl Taq was
used in addition to 5 μl template (cDNA). Thermocycler
conditions were set to the following: 50°C for two min,
95°C for 10 min, 40 cycles of 95°C for 30s-60°C for 30s-
72°C for 30s and a final 72°C for ten min [87,88]. The
primers used in the qRT-PCR were designed based on
the sequences for LacZ (F: TTGAAAATGGTCTGCT
GCTG, R: TATTGGCTTCATCCACCACA) and PGK-1
(F: CAGACCATTCTTGGCCATT, R: CGAAGATGGA
GTCACCGATT). PGK-1 (phosphoglycerate kinase) was
selected as the positive control due to being one of the
most highly expressed genes in yeast, producing up to
5% of total mRNA content [89].
Prediction and analysis of candidate biomarkers for
seasonal allergic rhinitis
40 patients with SAR were included in the study. SAR
and symptom scores were defined as previously de-
scribed [70,90]. Their median (range) age was 28 (18–58)
and 19 were women. The mean ± SEM symptom score
of the 40 patients after treatment decreased from 15.7 ±
1.0 to 4.3 ± 0.6 (P < 0.0000001). The study was approved
by the Ethics Committee of the Medical Faculty of the
University of Gothenburg. Written informed consent
and questionnaire data sheets were obtained from all
patients.
Proteins from the acute phase response pathway, com-
plement signaling pathway, and glucocorticoids receptor
pathway were extracted from the Ingenuity pathway ana-
lysis (IPA) software. Interactors to these proteins were
predicted using PIPE. We included secreted, membrane
and cytoplasmic proteins, but excluded nuclear proteins.
We prioritized candidate biomarkers based on their
number of known and predicted interactions. Next, we
focused on proteins with a high number of predicted
interactions.
Proteins were examined by ELISA in nasal fluids from 40
patients with SAR before and after GC treatment. V-akt
murine thymoma viral oncogene homolog 2 (Akt2) was
with an ELISA kit from R&D Systems Inc. (Minneapolis,
MN, USA). Proline-rich protein BstNI subfamily 1 (PRB1),
proline-rich protein BstNI subfamily 2 (PRB2), v-yes-1
Yamaguchi sarcoma viral related oncogene homolog
(LYN) and stratifin (SFN) were analyzed with ELISA kits
from Uscnlife Life Sciences and Technology (Wuhan,
China). All experiments were performed according to the
manufacturer’s protocol. The Wilcoxon matched pairs
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groups. A P-value less than 0.05 was considered significant.
Graph algorithms for assigning protein complexes
To decompose the predicted protein pairs into putative
complexes, we applied a novel algorithm that combines
pre-existing graph-theoretic tools with hierarchical clus-
tering concepts. The algorithm has three independent
stages: the initialization stage, which consists of generat-
ing an initial set of clusters, the merge stage, which
determines which two clusters to merge next, if any, and
the glom stage, which evaluates vertices for inclusion
into a cluster. The initialization stage is run once, after
which the merge and glom stages run alternately until
either the desired number of clusters is reached or until
neither stage results in a change to any cluster.
Since initialization is an independent step, any initial
clustering may be used. It is not required that the initial
clustering be overlapping, although stages two and three
may grow the clusters so that the end result is overlap-
ping. We chose to use the set of all maximal cliques as
the initial clustering. A clique is a set of vertices with all
edges present; a clique is maximal if no vertex can be
added to it to form a larger clique. The set of maximal
cliques forms a natural overlapping clustering of a graph
with the most rigid requirements, namely that all edges
be present within each cluster. Real-world graphs often
have many small and medium sized maximal cliques,
and the protein prediction graph is no exception. These
clusters are then allowed to merge and grow in stages
two and three, gradually relaxing the stringency until the
desired number of clusters is reached. To enumerate all
maximal cliques, we used the well-known algorithm of
Bron and Kerbosch described in [91] with bitwise im-
provements from [92].
In the merge stage, the overlap of all clusters is evalu-
ated and the two clusters with the highest overlap pro-
portion are merged. If no two clusters overlap by a
proportion greater than a parameter m, then no clusters
are merged.
In the glom stage, every vertex not already belonging
to a particular cluster is considered for inclusion into a
cluster in similar fashion to the paraclique algorithm
described in [76]. Those vertices with connectivity pro-
portion greater than g, the glom factor, are added to the
cluster. The first time through the glom stage, every
cluster is considered. Subsequent glom stages only con-
sider the cluster newly created by the merge stage, as all
other clusters having already been considered.
In practice, calculating all pairwise overlaps to find the
highest degree of overlap can make the merge stage
computationally prohibitive. A small change, however,
yields a good approximation version that can be run
until the number of clusters is reduced to the pointwhere the exact version can take over. Rather than mer-
ging the clusters with the highest overlap, the approxima-
tion version merges the first two clusters encountered
with overlap at least a, the approximation parameter. For
the protein prediction graph, which was initialized with
more than 100,000 maximal cliques, we ran the approxi-
mation version until the number of clusters reached
20,000, at which point we switched to the exact version.
Ultimately, a list of 8,739 paracliques were identified and
characterized through a statistical analysis of the GO
annotations of each member protein.
Additional files
Additional file 1: Precision-Recall curve for H. sapiens PPIs. The
curves presents the Recall (True Positive Rate) against Precision including
homologs (dashed blue line) and with homologs removed (dotted pink line).
Additional file 2: List of H. sapiens interactions predicted in this
study. Each prediction is accompanied by a score, if the interaction was
previously reported (known) or novel, if both proteins are in the same
component, have the same function or involved in the same process (GO
ontology) as well as if they share a third party interaction.
Additional file 3: List of co-purifying proteins that interact with the
tagged chromatin-related bait proteins.
Additional file 4: Number interacting pairs where both proteins
have the same function (A) or are involved in the same cellular
process (B) for previously reported data compared with those
reported in this study only.
Additional file 5: List of interactions for fibroblast growth factors
(FGFs) and cyclin-dependent kinases (CDKs) and FGF regulators and
CDK inhibitor/activators. *are interactors that have not been previously
reported.
Additional file 6: List of hub proteins in H. sapiens ranked by the
number of neighbors for each protein.
Additional file 7: List of betweenness centrality proteins in
H. sapiens ranked by highest betweenness centrality measure.
Additional file 8: List of protein mutations associated with resistance
to breast cancer therapeutics doxorubicin and Trastuzumab.
Additional file 9: List of proteins from the acute phase response
pathway, complement pathway and glucocorticoids receptor pathway.
Additional file 10: List of paracliques identified in this study
including the member proteins for the paraclique, interactions in
the paraclique as well as GO tags for molecular function and
biological process shared by the members of the paraclique with
P-value 1E-06.
Additional file 11: Schematic representation of the interactions for
three putative complexes, paracliques, 1359 (A) 1409 (B) and 2164
(C). A high degree of interconnectivity is observed for these complexes.
Red and green edges represent previously reported (known), and novel
interactions, respectively.
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